Research in Aging Cell indicates that blood levels of particular small non-coding RNAs, which regulate gene expression, may influence how long a person lives.
Investigators evaluated 828 small non-coding RNAs in blood samples from 1,271 community-dwelling older adults 71 years of age and older who were participating in an ongoing study. They then used machine learning to develop a model that could predict survival at 2, 5, and 10 years based on baseline small non-coding RNAs, age, and clinical variables (demographics, lifestyle, mood, physical function, standard clinical laboratory tests, lipid and metabolite levels, and medical conditions).
The test worked especially well for predicting survival over the next 2 years. “One surprising finding involved a group of small non-coding RNA molecules called piRNAs”, said co–corresponding author Virginia Byers Kraus, MD, PhD, of the Duke Molecular Physiology Institute. Scientists have long known that piRNAs help protect DNA in reproductive cells, but their role in the rest of the body is still a mystery. In this study, nine piRNAs, all reduced in longer-lived individuals, were identified as potential therapeutic targets to prolong longevity.
“These results suggest that simple blood tests measuring piRNAs might one day help doctors better understand health and aging – and possibly even guide new treatments to help people live longer, healthier lives,” said Dr Byers Kraus.
Study finds genetic contribution to human lifespan is about 50% – more than double previous estimates
Photo by Matteo Vistocco on Unsplash
What determines how long we live – and to what extent is our lifespan shaped by our genes? Surprisingly, scientists believed for decades that the heritability of human lifespan was relatively low compared to other human traits, standing at just 20 to 25%; some recent large-scale studies even placed it below 10%. Now, a new study from the Weizmann Institute of Science, published in Science, presents an entirely different picture. According to the findings, genetics accounts for about 50% of variation in human lifespan – twice as much, or more, than previously thought.
The study was led by Ben Shenhar from the lab of Prof Uri Alon of Weizmann’s Molecular Cell Biology Department.
“For many years, lifespan was attributed mainly to non-genetic factors, fuelling scepticism about genetic determinants of longevity”
Using mathematical models and analyses of three large twin databases from Sweden and Denmark – including, for the first time in this context, a dataset of twins who were raised apart – the researchers showed that earlier heritability estimates were masked by high levels of extrinsic mortality, such as deaths caused by accidents, infections and environmental hazards. Filtering out such extrinsic factors was impossible in historic datasets because they provided no information about the cause of death. To compensate for this limitation, the researchers developed an innovative framework that included mathematical simulation of virtual twins to separate deaths due to biological ageing from those caused by extrinsic factors. The new results are consistent with the heritability of other complex human traits and with findings from animal models.
Science Numbers
Up to age 80, the risk of dying from dementia shows a heritability of about 70% – far higher than that of cancer or heart disease.
The results have far-reaching implications for ageing research and public health. “For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable scepticism about the role of genetics in ageing and about the feasibility of identifying genetic determinants of longevity,” says Shenhar. “By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of ageing and, potentially, to address it therapeutically.”
A new breakthrough in a rare genetic disease which causes children to age rapidly has been discovered using ‘longevity genes’ found in people who live exceptionally long lives – over 100 years old. The research, by the University of Bristol and IRCCS MultiMedica, found these genes which helps keep the heart and blood vessels healthy during ageing could reverse the damage caused by this life-limiting disease.
This is the first study, published in Signal Transduction and Targeted Therapy, to show that a gene from long-lived people can slow down heart ageing in a progeria model. Also known as Hutchinson-Gilford Progeria Syndrome (HGPS), Progeria is a rare, fatal genetic condition of “rapid-ageing” in children.
HGPS is caused by a mutation in the LMNA gene, which leads to the production of a toxic protein called progerin. Most affected individuals die in their teens due to heart problems, although a few, like Sammy Basso, the oldest known person with progeria, have lived longer. Sadly, late last year (24 October) at the age of 28 Sammy passed away.
Progerin damages cells by disrupting the structure of their nucleus leading to early signs of ageing, especially in the heart and blood vessels.
Currently, the only United States Food and Drug Administration (FDA)-approved treatment is a drug called lonafarnib, which helps reduce the build-up of progerin. A newer clinical trial is now testing lonafarnib in combination with another drug called Progerinin to see if the combination works better.
In this study, researchers from Bristol Heart Institute, Dr Yan Qiu and Professor Paolo Madeddu, in collaboration with Professor Annibale Puca’s team at IRCCS MultiMedica in Italy, sought to explore whether genes from supercentenarians could help protect children with Progeria from the damaging effects of progerin.
The team focused on a ‘longevity gene’ found in centenarians, called LAV-BPIFB4. Previous research has showed that this gene helps keep the heart and blood vessels healthy during ageing.
Using mouse models genetically engineered to have Progeria, the research team were able to show early heart problems like those seen in children with the disease. The team found that a single injection of the longevity gene helped to improve heart function, specifically diastolic function.
It reduced heart tissue fibrosis and decreased the number of ‘aged’ cells in the heart. The gene also boosted the growth of new small blood vessels, which could help keep heart tissue healthy.
The team then tested the effect of the longevity gene in human cells from Progeria patients. Their findings showed adding the longevity gene to these cells reduced signs of ageing and fibrosis, without changing progerin levels directly. This suggests the gene helps protect cells from the effects of progerin, rather than removing it. Importantly, the treatment doesn’t try to eliminate progerin but instead helps the body cope with its toxic effects.
Dr Yan Qiu, Honorary Research Fellow in the Bristol Heart Institute at the University of Bristol, said: “Our research has identified a protective effect of a “supercentenarian longevity gene” against progeria heart dysfunction in both animal and cell models.
“The results offer hope to a new type of therapy for Progeria; one based on the natural biology of healthy ageing rather than blocking the faulty protein. This approach, in time, could also help fight normal age-related heart disease.
“Our research brings new hope in the fight against Progeria and suggests the genetics of supercentenarians could lead to new treatments for premature or accelerated cardiac ageing, which might help us all live longer, healthier lives.”
Professor Annibale Puca, Research Group Leader at IRCCS MultiMedica and Dean of the Faculty of Medicine at the University of Salerno, added: “This is the first study to indicate that a longevity-associated gene can counteract the cardiovascular damage caused by progeria.
“The results pave the way for new treatment strategies for this rare disease, which urgently requires innovative cardiovascular drugs capable of improving both long-term survival and patient quality of life. Looking ahead, the administration of the LAV-BPIFB4 gene through gene therapy could be replaced and/or complemented by new protein- or RNA-based delivery methods.
“We are currently conducting numerous studies to investigate the potential of LAV-BPIFB4 in counteracting the deterioration of the cardiovascular and immune systems in various pathological conditions, with the goal of translating these experimental findings into a new biologic drug.”
South Africa is facing a major health transition. While the average life expectancy has nearly doubled over the past century, the quality of those additional years, commonly referred to as one’s ‘healthspan,’ remains under threat from non-communicable diseases (NCDs). This threat calls for a renewed national focus on prevention and early intervention to address the rapidly growing challenge.
The Healthspan Imperative
According to health data presented at the 2025 Momentum Healthcare Insights Summit, NCDs such as heart disease, cancer, diabetes and neurodegenerative disorders now account for 51% of all deaths in South Africa. In contrast, communicable diseases make up around 40% and non-natural causes (like accidents and violence) account for a mere 9%. This shift reflects a global trend, although some challenges remain; infectious diseases become more manageable, while chronic conditions associated with lifestyle and ageing take centre stage.
Damian McHugh, Chief Marketing Officer at Momentum Health
“Medical advances have added years to our lives, but not necessarily life to our years. More and more, there is growing evidence to support the fact that prevention offers the greatest potential to reduce the burden as well as cost of chronic disease and improve quality of life,” says Damian McHugh, Chief Marketing Officer at Momentum Health.
Prevention Outperforms Treatment
The summit highlighted compelling evidence that prevention is more effective than treatment for advanced disease. For example, research from the American Cancer Society shows that tobacco control measures, such as smoking bans and taxes, have prevented 3.8 million lung cancer deaths in the United States since 1970. The most effective way to save lives from late-stage lung cancer has not been through treatment, but through reducing or eliminating smoking altogether.
The same principle applies to other chronic diseases. Managing risk factors such as high blood pressure, obesity, high blood glucose, and abnormal cholesterol can actively prevent or delay the onset of disease. These factors are strongly influenced by behaviours such as a lack of physical activity, poor nutrition, unmanaged stress levels, and even excessive alcohol use or smoking.
Investing in regular health check-ups and preventative care can mitigate the risk of serious health problems, ultimately reducing the incidence of costly, advanced illnesses. Simple lifestyle changes, such as prioritising rest and recovery, making time to connect with loved ones, maintaining balanced nutrition, practicing mindfulness, and engaging in regular exercise not only promotes physical and mental health, but can also translate into significant long-term savings in healthcare costs.
“Making quality healthcare more accessible, while enabling and rewarding healthy, preventative habits can lead to complete physical and mental health and wellbeing. Investing in access and wellbeing is a powerful pathway to realising more wealth and more health for more South Africans,” says McHugh.
Measuring and Managing Healthspan within the South African Context
Momentum Health’s data reveals that many South Africans are living longer, but the average age of medical scheme beneficiaries has increased by nearly three years over the past decade, and the proportion of pensioners in medical schemes is rising. Without proactive measures, our nation’s ailing healthcare system will face increasing claims and costs as the population ages and chronic diseases become more prevalent.
Momentum Health believes that the solution lies in taking measures to improve access to both quality medical care and reliable health information and empowering individuals to take responsibility for their own health.
South Africa’s rising NCD burden is not inevitable. With early detection, healthy lifestyle choices, and consistent engagement with preventative healthcare, individuals can not only extend their lifespan but also improve the years lived in good health.
“Prevention isn’t just a personal choice; it’s a public health imperative. By investing in wellness now, we can reduce the future burden on our healthcare system and help more South Africans enjoy longer, healthier lives,” concludes McHugh.
As revenues from the anti-aging market – riddled with hope and thousands of supplements – surged past $500 million last year, Emory University researchers identified a compound that actively delays aging in cells and organisms.
A newly published study in Nature Partner Journals’ Aging demonstrates that psilocin, a byproduct of consuming psilocybin, the active ingredient in psychedelic mushrooms, extended the cellular lifespan of human skin and lung cells by more than 50%.
In parallel, researchers also conducted the first long-term in vivo study evaluating the systemic effects of psilocybin in aged mice of 19 months, or the equivalent of 60–65 human years. Results indicated that the mice that received an initial low dose of psilocybin of 5mg/kg, followed by a monthly high dose of 15mg/kg for 10 months, had a 30% increase in survival compared to controls. These mice also displayed healthier physical features, such as improved fur quality, fewer white hairs and hair regrowth.
While traditionally researched for its mental health benefits, this study suggests that psilocybin impacts multiple hallmarks of aging by reducing oxidative stress, improving DNA repair responses, and preserving telomere length. Telomeres are the structured ends of a chromosome, protecting it from damage that could lead to the formation of age-related diseases, such as cancer, neurodegeneration or cardiovascular disease. These foundational processes influence human aging and the onset of these chronic diseases.
The study concludes that psilocybin may have the potential to revolutionize anti-aging therapies and could be an impactful intervention in an aging population.
“Most cells in the body express serotonin receptors, and this study opens a new frontier for how psilocybin could influence systemic aging processes, particularly when administered later in life,” says Louise Hecker, PhD, senior author on the study, and former associate professor at Emory, where the research was initiated and funded.
While much of what researchers know about psilocybin relates to the brain, few studies have examined its systemic impacts. Many people associate psilocybin with the hallucinogenic impacts, but the majority of the cells in the body express serotonin receptors.
“Our study opens new questions about what long-term treatments can do. Additionally, even when the intervention is initiated late in life in mice, it still leads to improved survival, which is clinically relevant in healthy aging,” adds Hecker, currently an associate professor at Baylor College of Medicine.
Not just a longer life, but a healthier life
“This study provides strong preclinical evidence that psilocybin may contribute to healthier aging – not just a longer lifespan, but a better quality of life in later years,” says Ali John Zarrabi, MD, director of psychedelic research at Emory’s Department of Psychiatry. “As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer – they experienced better aging,” adds Zarrabi, co-investigator of the study.
Zarrabi emphasises the importance of further research in older adults, as well as the well-documented overlap between physical and mental health.
“Emory is actively involved in Phase II and III clinical trials of psilocybin-assisted therapy for depression, and these results suggest we also need to understand psilocybin’s systemic effects in aging populations,” says Zarrabi. “My hope is also that if psilocybin-assisted therapy is approved as an intervention for depression by the FDA in 2027, then having a better quality of life would also translate into a longer, healthier life.”
In the study of 2268 US individuals aged 60 years and older who completed the Psychosocial and Lifestyle Questionnaires and provided blood samples in 2016, there was a strong association between engaging in social activities and a low risk of 4-year mortality. High social engagement was associated with a 42% lower mortality risk than low engagement.
Specific activities, such as charity work, engaging with grandchildren, and participation in sports or social clubs, were particularly significant predictors of a reduced risk of dying.
Also, analyses indicated that decelerated biological aging and greater physical activity levels played key roles in facilitating the beneficial relationship between social engagement and lower mortality rates.
“Staying socially active is more than a lifestyle choice. It is closely linked to healthier aging and longevity,” said corresponding author Ashraf Abugroun, MBBS, MPH, of the University of California, San Francisco. “These results underscore how participating in community life contributes to better health in older adults.”
In a decades-long study following twins, researchers from the University of Jyväskylä, Finland, investigated the links between long-term leisure-time physical activity and mortality. They also sought to determine whether physical activity can mitigate the increased risk of mortality due to genetic predisposition to diseases. Moreover, they examined the relationship between physical activity and later biological aging.
The study included 22 750 Finnish twins born before 1958 whose leisure-time physical activity was assessed in 1975, 1981 and 1990. Mortality follow-up continued until the end of 2020.
Moderate activity yields maximum longevity benefits
Four distinct sub-groups were identified from the data, which was based on leisure-time physical activity over the 15-year follow-up: sedentary, moderately active, active and highly active groups. When the differences in mortality between the groups were examined at the 30-year follow-up, it was found that the greatest benefit – a 7% lower risk of mortality – was achieved between the sedentary and moderately active groups. A higher level of physical activity brought no additional benefit.
When mortality was examined separately in the short and long term, a clear association was found in the short-term: the higher the level of physical activity, the lower the mortality risk. In the long term, however, those who were highly active did not differ from those who were sedentary in terms of mortality.
“An underlying pre-disease state can limit physical activity and ultimately lead to death, not the lack of exercise itself.”
“This can bias the association between physical activity and mortality in the short term”, says Associate Professor Elina Sillanpää from the Faculty of Sports and Health Sciences.
Meeting physical activity guidelines does not guarantee a lower mortality risk
The researchers also investigated whether following the World Health Organization’s physical activity guidelines affects mortality and genetic disease risk. The guidelines suggest 150 to 300 minutes of moderate or 75 to 150 minutes of vigorous activity weekly. The study found that meeting these guidelines did not lower mortality risk or alter genetic disease risk. Even for twins who met the recommended levels of PA over a 15-year period, no statistically significant difference in mortality rates was found compared to their less active twin pair.
“The widely observed favorable association between physical activity and mortality are based on observational studies that are prone to bias from different sources.”
“In our studies, we aimed to account for various sources of biases, and combined with the long follow-up period, we could not confirm that adhering to physical activity guidelines mitigates genetic cardiovascular disease risk or causally reduces mortality”, says postdoctoral researcher Laura Joensuu from the Faculty of Sports and Health Sciences.
Link between physical activity and biological aging is U-shaped
For the subsample of twins, biological aging was determined from blood samples using epigenetic clocks. Epigenetic clocks allow a person’s biological aging rate to be estimated based on methyl groups that regulate gene expression and are linked to aging process.
“We found that the association between leisure-time physical activity and biological aging was U-shaped: Biological aging was accelerated in those who exercised the least and the most,” says Sillanpää.
Other lifestyles, such as smoking and alcohol consumption, largely explained the favourable associations of physical activity with biological aging.
Genetic data were available for 4897 twins. The genetic susceptibility of twins to coronary artery disease, as well as systolic and diastolic blood pressure was assessed using new polygenic risk scores, which sum the genome-wide susceptibility to morbidity. In addition, all-cause and cardiovascular mortality was followed in 180 identical twin pairs. The biological aging rate of 1153 twins was assessed from a blood sample.
If everyone was as active as the top 25% of the population, individuals over the age of 40 could add five years to their life, according to a new study led by Griffith University researchers.
Physical activity has long been known to be good for health, however estimates have varied regarding how much benefit could be gained from a defined amount of activity, both for individuals and for populations.
This latest study, published in the British Journal of Sports Medicine, used US-based accelerometer data to gain an accurate view of a population’s physical activity levels instead of relying on survey responses as per other studies, and found the benefits were around twice as strong as previous estimates.
It found the most active quarter of people in the community had a 73% lower risk of death than their least active counterparts. For that least active quartile, a single one-hour walk could potentially return a benefit of around six additional hours of life.
Lead researcher Professor Lennert Veerman said this cohort had the greatest potential for health gains.
“If you’re already very active or in that top quartile, an extra hour’s walk may not make much difference as you’ve, in a sense, already ‘maxed out’ your benefit,” he said.
“If the least active quartile of the population over age 40 were to increase their activity level to that of the most active quartile however, they might live, on average, about 11 years longer.
“This is not an unreasonable prospect, as 25 per cent of the population is already doing it. It can be any type of exercise but would roughly be the equivalent of just under three hours of walking per day.”
The research team suggested low levels of physical activity could even rival the negative effects of smoking, with other research finding each cigarette could take 11 minutes from a smoker’s life.
By extension, a more active lifestyle could also offer protective effects against heart disease, stroke, certain cancers and other chronic illnesses, with the study’s findings highlighting a need for national physical activity guidelines to be revisited using these methods.
Dr Veerman said physical activity had been vastly underestimated in its capacity to improve health outcomes, suggesting even modest increases in movement could lead to significant life-extension benefits.
“If there’s something you could do to more than halve your risk of death, physical activity is enormously powerful,” he said.
“If we could increase investment in promoting physical activity and creating living environments that promote it such as walkable or cyclable neighbourhoods and convenient, affordable public transport systems, we could not only increase longevity but also reduce pressure on our health systems and the environment.”
Life expectancy increased dramatically over the 19th and 20th centuries, thanks to improvements such as healthier diets and medical advances. But after nearly doubling over the course of the 20th century, the rate of increase has slowed considerably in the last three decades, according to a new study led by the University of Illinois Chicago.
Despite frequent breakthroughs in medicine and public health, life expectancy at birth in the world’s longest-living populations has increased only an average of six and a half years since 1990, the analysis found. That rate of improvement falls far short of some scientists’ expectations that life expectancy would increase at an accelerated pace in this century and that most people born today will live past 100 years.
The Nature Aging paper offers new evidence that humans are approaching a biologically based limit to life. The biggest boosts to longevity have already occurred through successful efforts to combat disease, said lead author S. Jay Olshansky of the UIC School of Public Health. That leaves the damaging effects of aging as the main obstacle to further extension.
“Most people alive today at older ages are living on time that was manufactured by medicine,” said Olshansky, a professor of epidemiology and biostatistics. “But these medical Band-Aids are producing fewer years of life even though they’re occurring at an accelerated pace, implying that the period of rapid increases in life expectancy is now documented to be over.”
That also means extending life expectancy even more by reducing disease could be harmful, if those additional years aren’t healthy years, Olshansky added. “We should now shift our focus to efforts that slow aging and extend healthspan,” he said. Healthspan is a relatively new metric that measures the number of years a person is healthy, not just alive.
Life expectancy increased rapidly through the 19th century and first half of the 20th century. In 1990, some scientists predicted those rapid gains would continue, leading to “radical life extension.” But a new analysis proposes that we may be nearing the limit of human longevity. (Strategic Marketing and Communications / UIC)
The analysis, conducted with researchers from the University of Hawaii, Harvard and UCLA, is the latest chapter in a three-decade debate over the potential limits of human longevity.
In 1990, Olshansky published a paper in Science that argued humans were approaching a ceiling for life expectancy of around 85 years of age and that the most significant gains had already been made. Others predicted that advances in medicine and public health would accelerate 20th-century trends upward into the 21st century.
Thirty-four years later, the evidence reported in the 2024 Nature Aging study supports the idea that life expectancy gains will continue to slow as more people become exposed to the detrimental and immutable effects of aging. The study looked at data from the eight longest-living countries and Hong Kong, as well as the United States – one of only a handful of countries that has seen a decrease in life expectancy in the period studied.
“Our result overturns the conventional wisdom that the natural longevity endowment for our species is somewhere on the horizon ahead of us – a life expectancy beyond where we are today,” Olshansky said. “Instead, it’s behind us – somewhere in the 30- to 60-year range. We’ve now proven that modern medicine is yielding incrementally smaller improvements in longevity even though medical advances are occurring at breakneck speed.”
While more people may reach 100 years and beyond in this century, those cases will remain outliers that won’t move average life expectancy significantly higher, Olshansky said.
That conclusion pushes back against products and industries, such as insurance and wealth-management businesses, which increasingly make calculations based on assumptions that most people will live to be 100.
“This is profoundly bad advice because only a small percentage of the population will live that long in this century,” Olshansky said.
But the finding doesn’t rule out that medicine and science can produce further benefits, he said. There may be more immediate potential in improving quality of life at older ages instead of extending life, the authors argue. More investment should be made in geroscience – the biology of aging, which may hold the seeds of the next wave of health and life extension.
“This is a glass ceiling, not a brick wall,” Olshansky said. “There’s plenty of room for improvement: for reducing risk factors, working to eliminate disparities and encouraging people to adopt healthier lifestyles – all of which can enable people to live longer and healthier. We can push through this glass health and longevity ceiling with geroscience and efforts to slow the effects of aging.”
Photo by Mikhail Nilov: https://www.pexels.com/photo/a-couple-doing-yoga-at-home-7500701/
Flexibility exercises are often included in the exercise regimens of athletes and exercisers. New research in the Scandinavian Journal of Medicine & Science in Sports suggests that levels of flexibility may affect survival in middle-aged individuals.
After analysing data on 3,139 people (66% men) aged 46–65 years, investigators obtained a body flexibility score, termed Flexindex. This score was derived from a combination of the passive range of motion in 20 movements (each scored 0–4) involving 7 different joints, resulting in a score range of 0–80.
Flexindex was 35% higher in women compared with men. During an average follow-up of 12.9 years, 302 individuals (9.6%) comprising 224 men and 78 women died. Flexindex exhibited an inverse relationship with mortality risk and was nearly 10% higher for survivors compared with non-survivors in both men and women.
After taking age, body mass index, and health status into account, men and women with a low Flexindex had a 1.87- and 4.78-times higher risk of dying, respectively, than those with a high Flexindex.
“Being aerobically fit and strong and having good balance have been previously associated with low mortality. We were able to show that reduced body flexibility is also related to poor survival in middle-aged men and women,” said corresponding author Claudio Gil S. Araújo, MD, PhD, of the Exercise Medicine Clinic – CLINIMEX, in Rio de Janeiro, Brazil.
He added that as flexibility tends to decrease with aging, it may be worth paying more attention to flexibility exercises and routinely including assessments of body flexibility as part of all health-related physical fitness evaluations.
